ALN-AC3 / Alnylam - LARVOL DELTA

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides (clinicaltrials.gov) - P1; N=56; Completed; Sponsor: Ionis Pharmaceuticals, Inc.; Recruiting ➔ Completed; Trial completion date: Sep 2017 ➔ Apr 2018; Trial primary completion date: Sep 2017 ➔ Apr 2018

Trial completion • Trial completion date • Trial primary completion date • Biosimilar